HER2 Archives - Elixi International

18 January 2021

Enhertu (trastuzumab deruxtecan) first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer

18 April 2020

Tukysa (tucatinib) new option of treatment of adult patients with advanced forms of HER2-positive breast cancer

15 January 2020

Enhertu (fam-trastuzumab deruxtecan-nxki), new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies